Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612636 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Veronika S Mihailovskaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Ecology and Genetics of Microorganisms, Ural Branch of the Russian Academy of Sciences, Goleva Street 13, 614081 Perm, Russia. Hauptthemen laut MEDLINE: Escherichia coli Infections, Bacteriocins, Probiotics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Perm Krai, Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
Commensal bacteriocin-producing Escherichia coli are of interest for possible use as probiotics to selectively control the spread of pathogenic bacteria. Here, we evaluated the biosafety and efficacy of two new bacteriocin-producing E. coli strains, Q5 (VKM B-3706D) and C41 (VKM B-3707D), isolated from healthy farm animals. The genomes of both strains were sequenced, and genes responsible for the antagonistic and colonization abilities of each strain were identified. In vitro studies have shown that both strains were medium-adhesive and demonstrated antagonistic activity against most enteropathogens tested. Oral administration of 5 × 108 to 5 × 1010 colony-forming units of both strains to rats with drinking water did not cause any disease symptoms or side effects. Short-term (5 days) oral administration of both strains protected rats from colonization and pathogenic effects of a toxigenic beta-lactam-resistant strain of E. coli C55 and helped preserve intestinal homeostasis. Taken together, these in silico, in vitro, and in vivo data indicate that both strains (and especially E. coli Q5) can be potentially used for the prevention of colibacillosis in farm animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Ecology and Genetics of Microorganisms, Ural Branch of the Russian Academy of Sciences, Goleva Street 13, 614081 Perm, Russia.
- Skolkovo Institute of Science and Technology, 121205 Moscow, Russia.
- Department of Microbiology and Virology, Perm State Medical University Named after Academician E. A. Wagner, 614000 Perm, Russia.
- Institute of Gene Biology Russian Academy of Sciences, 119334 Moscow, Russia.
- Waksman Institute for Microbiology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
- Institute of Molecular Genetics, National Research Center "Kurchatov Institute", 123182 Moscow, Russia.
ORCID-Profile: Veronika S Mihailovskaya, Konstantin Severinov, Marina V Kuznetsova
Förderung
- Government of Perm Krai
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Mihailovskaya, V. S., Sutormin, D. A., Karipova, M. O., Trofimova, A. B., Mamontov, V. A., Severinov, K., & Kuznetsova, M. V. (2023). Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612636
Vancouver
Mihailovskaya VS, Sutormin DA, Karipova MO, Trofimova AB, Mamontov VA, Severinov K, et al. Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612636
BibTeX
@article{Mihailovskaya2023,
author = {Mihailovskaya, Veronika S and Sutormin, Dmitry A and Karipova, Marina O and Trofimova, Anna B and Mamontov, Victor A and Severinov, Konstantin and Kuznetsova, Marina V},
title = {Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612636}
}
EUVIMED